Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety.



from The Medical News http://ift.tt/1NiwsmU